GB A02
Alternative Names: GB-A02Latest Information Update: 12 Sep 2024
At a glance
- Originator GI Biome
- Class Antiallergics; Bacteria
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypersensitivity
Most Recent Events
- 31 Jul 2024 Preclinical trials in Hypersensitivity in South Korea (unspecified route) prior to July 2024 (GI Biome pipeline, July 2024)